title: Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up.
abstract: BACKGROUND
  Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown.
  
  
  METHODS
  A combined passive-active immunization programme for newborns of HBsAg-positive mothers was initiated in the north-eastern part of the Czech Republic in 1988. The number of immunized newborns had reached 665 newborns by the end of 2006. All mothers of immunized infants were HBsAg-positive during pregnancy, and 34 (5%) were also hepatitis B e antigen (HBeAg)-positive. The immunization programme consists of providing newborns with protection at birth with hepatitis B immunoglobulin, followed by three 10-μg doses of plasma-derived or, since 1990, recombinant vaccine administered at 0, 1 and 6 months of life. Only 29 children of HBeAg-positive mothers received vaccine at 0, 1 and 2 months of life. Blood samples were obtained after immunization, at 2 years of age, and biennially thereafter. Samples were tested for HBsAg and hepatitis B surface and core antibodies (anti-HBs, anti-HBc).
  
  
  RESULTS
  The immunization schedules were completed in 640 children. A protective anti-HBs level after immunization was proven in 574 of 620 children (93%). Persistence of protective anti-HBs antibodies was detected in 70, 40 and 25% of children at 5, 10 and 15 years of age. Vertical transmission with chronic HBsAg carrier status was detected in two infants. Anti-HBc seroconversion was proven in ten children from 3 to 15 years of age. Natural boosting with an anti-HBs increase was detected in 38 children (twice in one child).
  
  
  CONCLUSIONS
  Our results show that combined active-passive immunization of newborns against hepatitis B provides persistent protection up to adolescence despite a frequent waning of anti-HBs antibodies, suggesting there is no need for booster vaccination during adolescence.
authors.affiliation: Department of Infectious Diseases, University Hospital Ostrava, Tr 17. listopadu 1790, 708 52 Ostrava, Czech Republic. ludek.roznovsky@fnspo.cz
authors.forename: L
authors.initials: L
authors.lastname: Roznovsky
authors.forename: I
authors.initials: I
authors.lastname: Orsagova
authors.forename: A
authors.initials: A
authors.lastname: Kloudova
authors.forename: J
authors.initials: J
authors.lastname: Tvrdik
authors.forename: L
authors.initials: L
authors.lastname: Kabieszova
authors.forename: I
authors.initials: I
authors.lastname: Lochman
authors.forename: J
authors.initials: J
authors.lastname: Mrazek
authors.forename: L
authors.initials: L
authors.lastname: Hozakova
authors.forename: A
authors.initials: A
authors.lastname: Zjevikova
authors.forename: L
authors.initials: L
authors.lastname: Pliskova
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D018963:Hepatitis Antigens / Q000097:blood / Q000276:immunology; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006510:Hepatitis B Antibodies / Q000097:blood / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D011247:Pregnancy; D013995:Time; D014611:Vaccination
chemical_list: D018963:Hepatitis Antigens; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines